Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. (ATOS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
atos · stock forecast · 5 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$10.00
Consensus
$10.00
+119.8% upside
Low
$10.00
Median: $10 · Last Close: $4.55
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $4.40 | ↓ 3.22% |
1-day model range: $4.33–$4.48. Peak: $4.48 (-3.22%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -62.5% |
| 2029 | — | -67.2% |
| 2030 | — | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · ATOS · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-10 | Ascendiant Capital | Maintains | Buy→Buy |
| 2026-03-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-08 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-09-22 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-06-06 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-04-21 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-03-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Atossa Therapeutics, Inc. (ATOS) stock. Of the recent 28 rating actions, 1 were upgrades and 1 were downgrades. 5 analysts currently cover ATOS.
Analyst Recommendation Trends
ATOS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$54M
↓ 33.1% YoY
Revenue Next Year
$82M
↑ 51.2% YoY
EPS This Year
$-4.41
EPS Next Year
$-2.72
↓ 38.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast ATOS EPS of $-4.41 for the current fiscal year, based on estimates from 2 analysts. The ATOS revenue forecast is $54M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ATOS stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ATOS price target is $10.00 (+119.8% upside), with an analyst consensus of Buy.
The ATOS short-term stock prediction for tomorrow is $4.40 (-3.22%). The ATOS stock prediction for 2030 projects a range of $1–$2.
Atossa Therapeutics, Inc. trades on NASDAQ under the ticker ATOS. The ATOS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 80% of covering analysts.
Frequently asked questions
ATOS forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month ATOS price target is $10.00, with a high forecast of $10.00 and a low of $10.00. The median price target is shown in the chart above when available. This implies +119.8% potential upside from the current price of $4.55.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.